Porcine acute liver failure model established by two-phase surgery and treated with hollow fiber bioartificial liver support system.

AIM To establish a highly reproducible animal model of acute liver failure (ALF), for assessing the effect of bioartificial liver support system (BALSS). METHODS A two-phase complete liver devascularization procedure was performed in eight loco-hybrid pigs. Blood biochemical index and liver biopsy were studied every 2 h after surgery, and survival time was recorded. The BALSS constructed with high volume recirculating technique was a hollow fiber circulating system consisting of a hepatocyte reactor-hollow fiber module inoculated with microcarrier-adhering hepatocytes, and a double pump, heparinized, thermostabilized, micro-capsulized activated carbon-adsorbing plasmapheresis system. Twelve pigs undergoing two-phase surgery were randomized into: control group (perfused without hepatocytes, n = 6) and treatment group (perfused with hepatocytes, n = 6). Intergroup liver biochemical indexes, survival time, and liver pathological changes were analyzed at regular intervals. RESULTS Two-phase surgery was performed in all the experimental pigs, and there was no obvious difference between their biochemical indexes. After 3 h of phase II surgery, ammonia (Amm) increased to (269+/-37) micromol/L. After 5 h of the surgery, fibrinogen (Fib) decreased to (1.5+/-0.2) g/L. After 7 h of the surgery, ALT, AST, Tbil and PT were (7.6+/-1.8) nka/L, (40+/-5) nka/L, (55+/-8) micromol/L and (17.5+/-1.7) nka/L respectively. After 9 h of surgery, ALB and Cr were (27+/-4) g/L and (87+/-9) micromol/L. After 13 h of surgery, BUN was (3.5+/-0.9) micromol/L. All the above values were different from those determined before surgery. Survival time of pigs averaged 13.5+/-1.4 h. ALF pigs in the other group were treated with BALSS. The comparison analysis between the treated and control animals showed the changes of Tbil, PT, Alb, BUN, Cr, Fib, and Amm (P<0.01), but there was no change of ALT and AST. The survival time was statistically different (P<0.01), and there was no significant difference in histological changes. CONCLUSION The porcine ALF model established by two-phase devascularized surgery is valid and reproducible. The hollow fiber BALSS can meet the needs of life support and is effective in treating ALF.

[1]  P. Seglen.  Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. , 1973, Experimental cell research.

[2]  M. Ryska,et al.  Devascularization Surgical Model of Acute Liver Failure in Minipigs , 2004, European Surgical Research.

[3]  S L Nyberg,et al.  Apoptosis by gel-entrapped hepatocytes in a bioartificial liver. , 1999, Transplantation proceedings.

[4]  J. Rozga,et al.  In vitro morphological and functional characterization of isolated porcine hepatocytes for extracorporeal liver support: bile acid uptake and conjugation. , 1998, The Journal of surgical research.

[5]  T. Tani,et al.  Bioartificial liver support system using porcine hepatocytes entrapped in a three-dimensional hollow fiber module with collagen gel: An evaluation in the swine acute liver failure model. , 1999, Artificial organs.

[6]  Hanry Yu,et al.  Microcapsules with improved mechanical stability for hepatocyte culture. , 2003, Biomaterials.

[7]  A. Veitch,et al.  Oxygen transfer in a diffusion-limited hollow fiber bioartificial liver. , 2000, Artificial organs.

[8]  S. Levenson,et al.  Replacement of liver function in rats by transplantation of microcarrier-attached hepatocytes. , 1986, Science.

[9]  P. Seglen.  Preparation of rat liver cells. II. Effects of ions and chelators on tissue dispersion. , 1973, Experimental cell research.

[10]  G. Mazariegos,et al.  Novel Bioartificial Liver Support System: Preclinical Evaluation , 1999, Annals of the New York Academy of Sciences.

[11]  V. Dixit,et al.  The bioartificial liver: state-of-the-art. , 2003, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[12]  L. Flendrig,et al.  Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability. , 1999, Journal of hepatology.

[13]  T. Neuman,et al.  Bioartificial liver treatment in rats with fulminant hepatic failure: effect on DNA-binding activity of liver-enriched and growth-associated transcription factors. , 1999, The Journal of surgical research.

[14]  Achilles A. Demetriou,et al.  Development of a Hybrid Bioartificial Liver , 1993, Annals of surgery.

[15]  P. Rivas-Vetencourt,et al.  Xenotransplantation of isolated encapsulated porcine hepatocytes in the treatment of a highly fulminant hepatic failure model. , 1997, Transplantation proceedings.

[16]  J. Lehmann,et al.  Cultivation of immortalized human hepatocytes HepZ on macroporous CultiSpher G microcarriers. , 2000, Biotechnology and bioengineering.

[17]  P. Newsome,et al.  Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[18]  R. Busuttil,et al.  Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment: an ex vivo model of pig to human xenotransplantation. , 1999, Transplantation.